Drugs / EBV-TCR-T cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06119256 | Aug 2023 → Dec 2027 expected | Epstein-Barr virus infection | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06135922 | Aug 2023 → Dec 2026 expected | Epstein-Barr virus infection, secondary hemophagocytic lymphohistiocytosis | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT04156217 | Feb 2020 → Jul 2021 | post-transplant lymphoproliferative disease | Hebei Yanda Ludaopei Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV-TCR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04156217 ↗ |
| Modality | Cell therapy | “allogenic EBV-TCR-T cell therapy” NCT04156217 ↗ |
| Route | Intravenous | “will be intravenously infused” NCT04156217 ↗ |